Optimi Health to launch Phase 2 psilocybin trial for depression
Optimi Health Corp. has announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy in adults with major depressive disorder (MDD), with enrolment to begin in the first half of 2027 and dosing expected to conclude by the end of that year.
The trial, which has received authorisation from Health Canada, will enrol up to 200 participants across multiple Canadian sites. The primary endpoint is change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score, the standard clinician-rated measure used in depression trials. The study will include interim safety and efficacy readouts, with full topline data available once all participants have completed dosing and follow-up.
The trial design
Optimi says the study represents one of the largest clinical investigations of naturally derived psilocybin to date, distinguishing the programme from trials that use synthetic psilocybin. The company will supply product from its own Good Manufacturing Practice (GMP)-compliant facility in British Columbia, and will retain exclusive ownership of the resulting data.
Chief executive Dane Stevens said the trial marks the company's most significant clinical commitment to date and signals a strategic shift toward drug development alongside its existing manufacturing business. "Few companies in this sector are commercial today while also advancing their own clinical development," he said. "This trial builds directly on that foundation, and we can comfortably fund it with current cash on hand." Optimi holds a Drug Establishment Licence in Canada and has been supplying psilocybin through Health Canada's Special Access Programme.
Market context and regulatory landscape
MDD is estimated to affect around 332 million people worldwide, according to the World Health Organization, and a meaningful proportion of patients do not achieve adequate relief from conventional antidepressants. That treatment gap has driven substantial academic and commercial interest in psychedelic-assisted therapies, though the regulatory path to market authorisation remains demanding and largely uncharted for this drug class.
In the United States, the FDA issued draft guidance on psychedelic drug development in 2023, and several sponsors have programmes at Phase 2 stage. COMPASS Pathways, which is developing a synthetic psilocybin formulation for treatment-resistant depression, reported Phase 2b data in 2022 and has advanced into Phase 3. Usona Institute is pursuing a separate psilocybin programme in MDD. Optimi's use of naturally derived, botanically sourced psilocybin is a differentiating claim, though it will need to demonstrate comparable pharmacokinetic predictability to synthetic formulations to satisfy regulators.
Optimi's commercial position as an existing GMP manufacturer and Special Access Programme supplier gives it a degree of supply-chain credibility that many preclinical-stage entrants lack. The company's products are also prescribed to patients in Australia under the Authorised Prescriber Scheme, providing real-world supply experience. Whether that translates into a faster regulatory trajectory depends on the strength and consistency of the Phase 2 dataset, which investors and clinicians will assess once interim readouts emerge during 2027.
Health Canada has not granted market authorisation to any psilocybin product, and Optimi acknowledges in its release that the safety and efficacy of psilocybin-assisted therapy for MDD remains under investigation.